{"id":872244,"date":"2025-08-07T02:03:05","date_gmt":"2025-08-07T06:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/"},"modified":"2025-08-07T02:03:05","modified_gmt":"2025-08-07T06:03:05","slug":"almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/","title":{"rendered":"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Almirall selects second target in AI Drug Creation collaboration<\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Expanded collaboration builds on Absci\u2019s successful <\/strong><br \/>\n          <strong><br \/>\n            <em>de\u00a0novo<\/em><br \/>\n          <\/strong><br \/>\n          <strong> molecule design for difficult<\/strong><br \/>\n          <strong>\u2011<\/strong><br \/>\n          <strong>to<\/strong><br \/>\n          <strong>\u2011<\/strong><br \/>\n          <strong>drug targets in the first stage of the collaboration with Almirall<\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">BARCELONA, Spain and VANCOUVER, Wash., Aug.  07, 2025  (GLOBE NEWSWIRE) &#8212; Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3rb346pf3qP0HNmQ_Gnq8WdbFaoJn8RxdkjDjtUk004jTsyBp9FzrTUmsjKeyuCj1V2X3HuCTwGQGRW0wQwJXyf_1GtzQCtFxWWvWMvxZ-PB2khg_H6zLXD2Vcz8vUPD\" rel=\"nofollow\" target=\"_blank\">ABSI<\/a>), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall\u2019s selection of a second target aimed at dermatological indications.<\/p>\n<p align=\"justify\">The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target\u2014the first target addressed within the initial collaboration between Almirall and Absci. The collaboration, originally announced in November 2023, combines Absci\u2019s Integrated Drug Creation\u2122 platform with Almirall\u2019s dermatology expertise to accelerate the development of novel and breakthrough therapeutics for chronic and debilitating skin diseases.<\/p>\n<p align=\"justify\">\u201cUsing advanced AI capabilities to design therapeutic candidates against historically challenging disease targets is a highly promising approach and Absci\u00b4s <em>de-novo <\/em>AI platform capabilities have already demonstrated early success\u201d said Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall. \u201cWe are pleased to expand our collaboration as we continue to harness AI to help us develop innovative treatments for patients living with severe skin conditions.\u201d<\/p>\n<p align=\"justify\">Under the terms of the collaboration, Absci is leveraging its generative AI platform combined with its wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development programs of those candidates. Absci is eligible to receive up to approximately $650 million in upfront, R&amp;D, and post-approval milestone payments across both programs, plus royalties on potential product sales.<\/p>\n<p align=\"justify\">\u201cThe progress in our collaboration is a testament that AI <em>de novo<\/em> drug design is a successful approach to unlock novel biology where traditional drug discovery approaches have failed,\u201d said Sean McClain, Founder and CEO of Absci. \u201cWe\u2019re proud of this milestone and excited to deepen our collaboration with Almirall with the goal of bringing a new generation of AI-created therapeutics for dermatology patients.\u201d<\/p>\n<p align=\"justify\">The expansion of the collaboration to include a second program is at the heart of the shared commitment of both companies &#8211; to accelerate innovation in dermatology by using generative AI to enable new therapeutic approaches.<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong> Almirall<\/strong>\n      <\/p>\n<p>Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: <em>to transform the patients&#8217; world by helping them realize their hopes and dreams for a healthy life<\/em>. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients\u00b4 needs.<\/p>\n<p>Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: \u20ac990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.<\/p>\n<p>\n        <strong>For more information, please visit <\/strong><br \/>\n        <strong><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OiVvib-ClV3wWPzzxFbIQrjcrCbMpqJ1OYfDc_W3IclVNfvtZor1SJ_gsMDvfJjBwuXc_DSpQ8YNSIo5YNN_zYbgeW1YN3-muD0kQ3dZQdc=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.almirall.com\/<\/a><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Corporate Communications:<\/strong>\u00a0<\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Investor Relations<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong><br \/>\n              <a href=\"mailto:corporate.communication@almirall.com\" rel=\"nofollow\" target=\"_blank\">corporate.communication@almirall.com<\/a><br \/>\n            <\/strong>\n          <\/td>\n<td>\n            <strong><br \/>\n              <a href=\"mailto:investors@almirall.com\" rel=\"nofollow\" target=\"_blank\">investors@almirall.com<\/a><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Phone: <\/strong><br \/>\n            <strong>+34 93 291 35 08<\/strong>\n          <\/td>\n<td>\n            <strong>Phone: (+34) 93 291 30 87<\/strong>\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Absci<\/strong>\n      <\/p>\n<p>\n        <em>Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation\u2122 platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci\u2019s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bgXiIW9prE_xPmclxwrvA_aJtA0kcN_V6UHvPdKQew7jU-vUUBwKzgE6WKI5UtESSeEOjcmnnv5vwqdNLzQm_wTKVsdgvcdGrRWaqtFWlcHLDI_aawyDn5uk1EcvCZc2kMLoFaByl3C7aN6vXkDvtqT9lB1v7bcGBunDwqbA2E3MjU3NT7Nz-nG9j8Hzkz0M4L8nU_fDYqGmZFUGILA2B-LUm3AW6rPsnDMcsSPWahs=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em> www.absci.com<\/em><br \/>\n        <\/a><br \/>\n        <em> or follow us on LinkedIn (<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r5jL8lmesPSWSOws8sJacTiyvqQD6JZHc28MxqJk68QCzUrAPGZJDzjFCmlpfeFnNjZ4cXtZONYaqhqkJcmzVXNQbQ3uTds42Xj7rlVCkpxbgsQzoBo_5ng4NRn78rA5CGTDsDqgqvnUkxkXt35-zOJYi6LCDE4V7an-I4mDHalDIlpMrjO_gHbNgoYxCdqmc-C4ceXZUfMNfQ3rTRdqoOCcJ2AwhNFaP1N_1K2uBCIMljP_baJm965mKO9ZKMh8\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>@absci<\/em><br \/>\n        <\/a><br \/>\n        <em>), X (<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bKY5M79uj3T8SA_GX5ZwwV0w8qMGgbwdrlriUpB3xjSSp1u-LxRD-fAPfhhuO4XKGgC2b1T6LC3OIU6QEYr22ui7ZYAyPezxOJBn8Yv7a25ue5o0VWQCwM1FMY0jFm4Gx5yOOhYaQs5Pl9fVLRhMQrc8WKhn56cV73j30KqJPnB_ZKCJf-XDedcwYGU_d6QXrz1hnWVHr-t48D3JCVEQzS_ON_L6-veOtggZQOqzX2U=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>@Abscibio<\/em><br \/>\n        <\/a><br \/>\n        <em>) and <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pjgQQA3VopPiiDxzlLGoJnNmsxdGlC0O9P-cFV8-YvXR7qpkgjepE_5p6yFQDcNGAhDDX-8MdFz2KvpjrscU_UCKBpZBOgVciOFLdNWKTrr6Ze4HgQs-KLenxhZEzk1y38BpmMcSEYjMGConZnwnHpO4ecFHzOIZZpo2xsv1htncjagdjMQ-h2-wPcG86arw0wKUkUPJw1bS6vWSriw7M4wSWjPs_d00NeqSvEfHUE4=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>YouTube<\/em><br \/>\n        <\/a><br \/>\n        <em>.<\/em>\n      <\/p>\n<p>\n        <em>Absci Media Contact<\/em><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tVNZA2_6IqQtOI4JeXrFWOhfVO6ZpdSSrFdbyutBuSgQzjT4WDqQlSHAhDDdvvbw28R3Qq03tsIl8_LMSgEc39pl8Jaxg4wZaXUSCuEIBr_mRf63HCRPpbFHQzyX-POyjiwb8gAxqTqSP446gj-rz9RijXIVHUBPsLmNuLkBgc4aR7sC9SQ9492XTk0pbZoowS4eJZp9Kai9NlSDEhfxV2CGXmKgM7dyewcguPiQutQ=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>press@absci.com<\/em><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <em>Absci Investor Contact<\/em><br \/>\n        <br \/>\n        <em>Alex Khan<\/em><br \/>\n        <br \/>\n        <em>VP, Finance &amp; Investor Relations<\/em><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FX3NhzeOx_foVE1S3pE3et-7HOqk5bmYyHKsYmHimyGwYhzj6t7UGBMbjvAh03z93mbH-PRoYmXjzhAlCULb1addnS12XUhU2MZbUW038HRNDpOKFyNr9Dz-lW0n5r2Thl6oiiAgglQgcMNOSYGTOffE9-oaMs3ozKGb9wqB4LK_vJcQJLnZ1e2dJbEKi3y4-Ki0bYVAJxbNbD71RZEPk_kULs0mznvRgslcreEyDr2twRc62Dba-UPhJ74-emkp5lyDN-9slrqxfLgkoi4avg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>investors@absci.com<\/em><br \/>\n        <\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDhkZTg1YjYtY2MyZC00ZTQwLWI0OTAtNWNiODBiODc3YjBjLTEyMjE2MzMtMjAyNS0wOC0wNy1lbg==\/tiny\/ABSCI-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci\u2019s successful de\u00a0novo molecule design for difficult \u2011 to \u2011 drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall\u2019s selection of a second target aimed at dermatological indications. The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target\u2014the first target addressed within the initial collaboration between Almirall &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-872244","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci\u2019s successful de\u00a0novo molecule design for difficult \u2011 to \u2011 drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall\u2019s selection of a second target aimed at dermatological indications. The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target\u2014the first target addressed within the initial collaboration between Almirall &hellip; Continue reading &quot;Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T06:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target\",\"datePublished\":\"2025-08-07T06:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/\"},\"wordCount\":724,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/\",\"name\":\"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=\",\"datePublished\":\"2025-08-07T06:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/","og_locale":"en_US","og_type":"article","og_title":"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target - Market Newsdesk","og_description":"Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci\u2019s successful de\u00a0novo molecule design for difficult \u2011 to \u2011 drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall\u2019s selection of a second target aimed at dermatological indications. The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target\u2014the first target addressed within the initial collaboration between Almirall &hellip; Continue reading \"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-07T06:03:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target","datePublished":"2025-08-07T06:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/"},"wordCount":724,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/","name":"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=","datePublished":"2025-08-07T06:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzY0NCM3MDg1MzQ0IzIyMTAwODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=872244"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872244\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=872244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=872244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=872244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}